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the TIMI score and 0.87 for the TIMI-NBNP score. Conclusion: Although the cohort of 
patients is relative small, we could demonstrate the importance of additional measure- 
ment of NBNP levels for risk stratification in patients with UAINSTEMI. 
1126-105 Serum Creatinine, Creatinine Clearance, and Long-Term 
Mortality Afler Non-ST Elevation Acute Coronary 
Syndrome Treated Very Early and Predominantly With 
Percutaneous Coronary Intervention 
Christian Mueller, Franz-Josef Neumann, Helmut Roskamm. Andre P. Perruchoud. 
Heinz J. Buettner, University Hospital, Easel, Switzerland, HewZentrum, Bad 
Krozingen, Germany 
Background: Very early revascularization is the most contemporary management strat- 
egy in non-ST-elevation acute coronary syndromes (NSTACS). Predictors of outcome 
with this strategy are poorly defmed. We sought to quantity the impact of baselme renal 
dysfunction on short and long-term mortality in patients with NSTACS treated with an 
very early invasive strategy. Methods: We conducted a prospective cohort study in 1400 
consecutive patients with NSTACS undergoing coronary angiography and subsequent 
coronary stenting of the culprit lesion as the primary revascularization strategy within 24 
hours of admission. Mortality in-hospital and at 3 years was stratified according to quar- 
tiles of serum creatinine and corrected creatinine clearance determined on admlssion. 
Results: Kaplan-M&r survival analysis demonstrated a cumulative 3.year survival of 
95.3% in the first (co.71 mg/dL), 95.1% in the second (0.71-0.84 mg/dL), 92.9% in the 
third (0.84-1.00 mg/dL), and 83.1% in the fourth quartile of serum creatinine (2 1.00 mgl 
dL) (p<O.OOl). For the quartiles of creatinine clearance (<68, 68-85, 85105, 2 105 ml./ 
min), cumulative 3-year survival was 82.0%, 91.3%, 95.7% and 96.9%, respectively 
(p<O.OOl). Patients in the highest quartile (t 1 .OO mg/dL) of serum creatinine wan? six 
times more likely to die in-hospital (hazard ratio 6.1, [95% Cl 2.6 to 14.1); pcO.001) and 
almost four times more likely to die during long-term follow-up (hazard ratio, 3.8 [Cl 2.4 to 
5.81; pcO.001). By multivariate Cox regression analysis, serum creatinine in the highest 
qualtile remained a strong independent predictor of mortality. Conclusion: Baseline 
renal dysfunction is a strong independent predictor of in-hospital and long-term mortality 
after NSTACS treated with very early revascularization. 
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827-l How Important Is Time to Treatment With Primary 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction? Results From the CADILLAC 
Trial 
Bruce R. Brodie, David A. Cox. Thomas D. Stuckey, Mark Turco, Eulogio Garcia, John J. 
Griffin, Martin Fahy, James E. Tcheng, Cindy L. Grines, Roxana Mehran, Gregg W. 
Stone, LeBauer Cardiovascular Research Foundation, Greensboro, NC, Cardiovascular 
Research Foundation, New York, NY 
Background: Time to treatment is critlcally important with thrombolytic therapy, but may 
be less impoltant with primary PCI. 
Methods: The CADILLAC Trial enrolled pts with AMI ~12 hrs without shock who were 
randomized to stenting vs PTCA +I- abciximab. Treatment time data were available in 
2,002 pts. 
Resulb: Median (25” and 75m percentiles) time from symptom onset to ER was 1.8 hrs 
(1 .O, 3.4), from ER to balloon inflation (DB time) was 2.0 hrs (1.5, 2.7) and from symptom 
onset to balloon Inflation @perfusion time, AT) was 4.0 hrs (2.9, 6.1). RT (hrs) was 
longer at US sites (4.0 vs 3.7, p=O.O02), in women (4.6 YS 3.8, p<O.OOOl). diabetics (4.6 
vs 3.6, p<O.OOOl ), and pts with CFX infarcts (4.4 YS 3.9, p=O.O003). Mortality (30 day 
and 1 yr) was lowest with RT < 3 hrs and there was a trend for lower 1 yr re-infarction 
with RT < 3 hrs (Table). After 3 hrs. further treatment delays had little impact on mortality. 
DB times (cl .5 vs 1.5-2.0 vs >2.0-3.0 YS z.3.0 hrs ) had little effect on 1 yr mortality (3.4% 
vs 4.3% “s 4.2% “s 4.6%. p=NS). 
Conclusions: Early repelfusion (c 3 hrs) with primary PCI is associated with better 30 
day and 1 yr survival and a trend toward less m-infarction at 1 yr. Delays beyond 3 hrs 
have little effect on survival. These data emphasize the importance of early repeltuslon 
and have implications regarding pt triage and the mechanism of benefit of reperfusion 
therapy with primary PCI. 
TIMI 3 Flow Post-PC1 
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027-2 Baseline Features and Clinical Results in Patients 
Excluded From Randomization From a Large 
International Trial of Reperfusion Strategies in Acute 
Myocardial Infarction: The CADILLAC Registry 
Mark A. Turco, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, Giulio 
Guagliumi, Thomas D. Stuckey, John D. Carroll, Cindy L. Grines, Barry D. Rutherford. 
Steve Slack, Martin Fahy, Roxana Mehran, Alexandra J. Lansky, Gregg W. Stone, 
Center for Cardiac & Vascular Research and Washington Adventist Hospital, Takoma 
Park, MD, Cardiovascular Research Foundation and Lenox Hill Heart and Vascular 
Center, New York, NY 
Background:The randomized CADILLAC trial was performed to compare PTCA versus 
stenting with or without abciximab, in AMI patients of any age without cardiogenic shock 
presenting c12hrs from symptom onset. Patients meeting these criteria but who were 
excluded from randomization for a variety of pm-specified angiographic reasons were fol- 
lowed in an in-hospital registry. 
Aesults:Of 2,681 AMI pts consented, 599 (22%) were not randomized, most commonly 
because of extensive LM/9vessel disease (38%), vessel size <2.5mm or >3.75mm 
(23%), excessive tortuosity (17%), calcification (16%), unprotected LM or ostial disease 
(16%). or non-identifiable culprit (15%). Compared to randomized pts, those in the regis- 
try were more likely to be older (69 vs 52 yrs, p=O.O02), have prior Ml (20% vs 14%, 
p=O.OOOl), prior CABG (12% vs 2%, p<O.OOOl), 3-vessel disease (52% vs 15%, 
pcO.OOOl), lower LVEF (45% vs 50%, p=O.OOOl), and fewer inferior infarcts (47% vs 
56%. p=<O.OOi). Pts in the registry were treated either medically (38%), by PCI (39%) or 
wth CABG (23%). Comparative outcomes are reported below. 
In Hospital Outcome Registry Randomized P-Value 
NS99 N=2082 
Final TIMI 3 80% 95% <O.OOl 
Death 4.0% 1.6% 0.001 
Reinfarction 0.3% 0.2% NS 
Revascularization 14.0% 2.5% <O.OOl 
Stroke 0.5% 0.5% NS 
MACE 18.0% 4.6% <O.OOl 
Conclusions: Although 78% of consented pts (and 90% of those undergoing PCI) were 
randomized in CADILLAC. pts with AMI excluded from randomization on angiographic 
grounds comprised an extremely high risk cohort with multiple adverse baseline features, 
lower procedural success, and diminished event-free wvival. These data partly explain 
differences between AMI trials that randomize pts before versus after angiography. 
4:30 pm. 
827-3 Relationship Between Time-to-Reperfusion and 30-Day 
Mortality in Patients With ST-Segment Elevation 
Myocardial Infarction Treated With Primary Angioplasty 
Giuseppe De Luca, Harry Suryapranata, Arnoud W. van t’ Hof, Jan C. Hoorntja, Menko- 
Jan de Boer, Jan-Henk Dambrink, Felix Zijlstra, Hospital De Weezenlanden, Zwolle, The 
Netherlands 
Background. Even if time-to-reperfuslon has been demonstrated to be a main predictor 
of outcome in patients with ST-elevation myocardial Infarction (STEMI) treated with 
thrombolysis, still controversial remains Its prognostic role in patients treated with primary 
angioplasty. 
Methods. A total of 1791 patfents with STEMI treated wth primary angioplasty at our 
Institution from 1994 to 2001, represent the population of the current study. All clinical, 
angiographic. and follow-up data were collected. According to time-to-reperfusion. 
patients were dwided in 4 groups: Group 1 (c 2 hours), Group 2 (2-4 hours), Group 3 (4. 
6 hours), Group 4 (> 6 hours). A multivariate analysis was performed to identify indepen- 
dent predictors of 30-day mortality. 
Results. At multivariate analysis, a time-to-reperiusion > 4 hours was an independent 
predictors of 30.day mortality. 
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Table 
Group 1 (n = Group 2 (n = Group 3 (n = Group 4 (n = p 
226) 1065) 427) 73) value 
TIMI 3 post 93.4 91.3 86.9 90.4 0.012 
(%) 
30-day 
death 
3.1 2.5 5.6 9.6 0.001 
Conclusion. Our study shows that time-to-reperfusion is a prognostic determinant of out- 
come in patients with STEMI treated with primary angioplasty. Thus, all efforts (an early 
diagnosis and a rapid transportation to an angioplasty center)should be done to revascu- 
larize patients with STEMI within 4 hours after symptom onset. 
4:45 pm 
827-4 Multiple Lesion Coronary Intervention Is Associated 
With Higher Mortality in Primary Angioplasty for Acute 
Myocardial Infarction: The Stent PAMI Trial 
Greaorv G. Pellizzon, Kishore Harjai. Srinivas Addala, Anthony Ochoa, Gregg W. Stone, 
David A. Cox, Lorelei Grines, Judith A. Boura, Bruce R. Brodie. William W. O’Neill, Cindy 
L. Grines, William Beaumont Hospital, Royal Oak, MI 
Background: The optimal revascularization strategy for patients with acute myocardial 
infarction (AMI) found to have multiple lesions dung primary percutaneous coronary 
!ntervention (PCI) remains unknown. We determined the safety of revascularizing a non- 
culprit lesion (NCL) during primary PCI for AMI. 
Methods: We examined 473 AMI patients undergoing pnmary PCI who had a NCL 
(defined as z 50% angiographic stenosis). We compared angiographic and clinical out- 
comes in patients in whom the NCL was treated during primary PCI (group A, N=lOl) 
versus patients whose NCL was left untreated (group B, N=372). 
Results: Initial and final TIMI 3 flow and ejection fraction were similar. Group A patients 
had less multivessel disease (pcO.0001) but more diseased segments in the infarct 
related artery (IRA) (p-zO.0001). All but 2 patients had NCL intervention performed within 
the IRA. Outcomes for group A and group B were similar; at 1 year, reinfarction (3% vs. 
4.3%) and ischemic TVR (16% vs. 18%) and total revascularization (37% vs. 34%) were 
slmllar. Group A patients had a higher total mortality at 1 year (9.9% vs. 4.3%, pzO.029) 
and a trend to higher cardiac mortality (6% vs. 3.5%, ~~0.26). By multivariate analysis, 
treatment of NCL remamed an independent predictor of total mortality at 1 year (OR 
3.03, p=O.OOSS). Conclusion: Multiple lesion PCI is safe acutely but associated with 
greater late mortality in patients undergoing primary PCI for AMI. These data suggest 
avoiding treatment of the NCL in the IRA 
S!i 
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No Mortality Benefit of Primary Angioplasty Over 
Thrombolytic Therapy in Patients With Nonanterior 
Myocardial Infarction at Long-Term Follow-Up: Results 
of the Zwolle Trial 
Arnoud W. van ‘t Hof , Jose Henriques, Jan-Paul Ottervanger, Jan Henk Dambrmk, 
Marcel Gosselink, Jan C. Hoorntje. Menko Jan de Boer, Felix Zijlstra, lsala Klinieken, lx 
Weezenlanden, Zwolle, The Netherlands 
Background. Primary angioplasty (PA) has been shown to be an effective reperfusion 
therapy in pts with acute myocardial Infarction (AMI). However, only few studies specifi- 
cally addressed the extent of benefit over thrombolytic therapy according to infarct loca- 
tion. 
Methods. From 1990 to 1995, 395 pts with AMI were randomized to i.v. streptokinase 
(SK) or PA at our center.244 (62%) pts had non-anterior MI. defined as ST elevation of 1 
mm in at least 2 contiguous inferw leads. Follow-up information was obtained in Sep- 
tember 2000. Survival was calculated by the Kaplan-Meler pruduct-limit method. The log 
rank test was used to evaluate differences in survival. 
Results. During a median of 8 yr follow-up, a total of 105 pts died (26.5%). Kaplan-Meier 
survival curves are shown in the figure. For the combined incidence of death and re-inf- 
arction (re-MI), PA was superior to SK for both anterior and non-antenor Ml (Non-Ant 
PA:28/117 (23.9%); SK:50/127 (39.4%). P<O.Ol, Ant: PA: 25177 (32.5%);SK:44/74 
(59.5%). p.z0.001). 
Conclusion. A large mortality benefit was found in pts with anterior Ml treated with PA 
compared to SK. For pts with non-anterior MI no difference in mortality was found at long 
term follow-up. For the combined incidence of death and ra MI, PA was superior to SK for 
both anterior and non-anterior Ml. 
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827-6 Randomized Trial of Primary Angioplasty Versus 
Prehospital Hibrinolysis in Acute Myocardial Infarction: 
One-Year Survival Results 
Alain Leizorovicz, Paul Touboul, Eric Bonnefoy, Oliwer Piegay, CAPTIM Group, School 
of Medrcine RTH Laennec, Lyon, France 
Background 
Prehospital fibrinolysis and primary angioplasty have been shown to provide a clinical 
benefit over in-hospital fibrinolysis in acute myocardial infarction (AMI) We did a ran- 
domized trial to compare directly these strategies on clinically r&vent outcomes, cardio- 
vascular events and mortality at short term and long term mortality. 
Methods 
Patients who presented within 6 hours of acute ST-segment elevation myocardial infarc- 
tion, initially managed by mobile emergency care unit personnel, were randomized to 
prehospital fibrinolysis (n=419) with accelerated alteplase (e-PA) or to primary angio- 
plasty (n=421) All were transferred to a centre with access to emergency angioplasty. 
The primary endpoint was a composite of death, nonfatal reinfarction. and nonfatal dis- 
abling stroke at 30 days. Secondary endpoints included total death at 30 days, at one 
year and at a common cut off date, one year after the lnclus~on of the last patient. 
Results 
The incidence of the primary endpoint (already reported) in the prehospital fibrinolysis 
and primary angloplasty groups was 8.2% and 6.2% respectively (p = 0.29). 
Death at 30 Days occurred in 3.8% of the patients assigned to prehospital fibrinolysis 
and 4.8% of those assigned to primary angioplasty (P=O.61). 
Total mortalty 
Angioplasty RR (95% Cl) P value 
Fibrinolysis 
End of follow up 28/419 (6.7%) 371421 (8.8%) 1.31 (0.82 ; 2.11) 0.25 
One year 221408 (5.4%) 30/412 (7.3%) 1.35 (0.79 ; 2.30) 0.27 
Conclusion 
In this low risk AMI population, the long term mortality results confirm the trends already 
observed at 30 days with no clear major advantage of primary angioplasty over pre-hos- 
pital fibrinolysis in terms of survival. 
